This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

THE TOXOPLASMOSIS STUDY GROUP
114 Baumgarten Pavilion Michael Reese Medical Center 31st Street and South Lake Shore Drive Chicago, IL 60616

Am J Dis Child. 1990;144(6):619.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Sir.—The article by Koskiniemi et al¹ that appeared in the June 1989 issue of AJDC illustrates the great need for controlled data concerning optimal means to diagnose and treat congenital toxoplasmosis. We are conducting a randomized, prospective study to evaluate treatment and outcome of patients with congenital toxoplasmosis. This national collaborative study is supported by the National Institutes of Allergy and Infectious Diseases, the March of Dimes, and the Food and Drug Administration, Orphan Drugs Division.

Patients are stratified based on severity of their disease. They are then randomized to one of three treatment regimens, which include pyrimethamine, sulfonamides, folinic acid, and spiramycin.

To ensure uniform evaluation, patients are evaluated at the study center in Chicago, Ill, at ages 0 to 2 months and 1, 3.5, 5.5, 8, and 15 years. Evaluation includes assessments of the patient's immunologic response to Toxoplasma gondii and assessments by specialists in pediatric . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?